Loading…
Conexeu Sciences Inc. is projected to decline to $9.47 by 2027, a -7% move from its current price of $10.20. Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $9.49 | $10.20 | $10.97 | 0.00% |
| Jul 15 | $9.20 | $10.20 | $11.30 | 0.00% |
| Jul 16 | $8.99 | $10.20 | $11.57 | 0.00% |
| Jul 17 | $8.82 | $10.20 | $11.79 | 0.00% |
| Jul 18 | $8.67 | $10.20 | $12.00 | 0.00% |
| Jul 19 | $8.54 | $10.20 | $12.19 | 0.00% |
| Jul 20 | $8.42 | $10.20 | $12.36 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.42 | $10.20 | $12.36 | +0.01% |
| Week 2 | $7.77 | $10.20 | $13.39 | +0.01% |
| Week 3 | $7.31 | $10.20 | $14.23 | +0.02% |
| Week 4 | $6.95 | $10.20 | $14.98 | +0.02% |
| Week 5 | $6.64 | $10.20 | $15.68 | +0.03% |
| Week 6 | $6.37 | $10.20 | $16.33 | +0.03% |
| Week 7 | $6.14 | $10.20 | $16.96 | +0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration.
CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications.
The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
CNXU is the stock ticker for Conexeu Sciences Inc., a healthcare company by sector. The current price is $10.24 and the market capitalization is $274.01M. The shares are ranked 3586 by size within the market.
The year-by-year forecast shows a mixed trajectory around the current level in the near term, with potential upside later in the decade. The 2026 average price is $10.24 with a 0% ROI, and the 2040 average price is $16.70 with a 63% ROI, followed by a 2050 average price of $20.04 yielding a 95.7% ROI. The forecast also indicates oscillating sentiment across years, turning bullish in 2040 and 2050.
A major floor 52.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 65.2% above — a clean break opens room to run.
A major ceiling 91.6% above — clearing it would confirm fresh momentum.
Key CNXU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNXU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.13 | Buy | $10.18 | Buy |
| MA 10 | $10.39 | Sell | $10.45 | Sell |
| MA 20 | $10.98 | Sell | $11.09 | Sell |
| MA 50 | — | Neutral | — | Neutral |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.86 | Neutral |
| Stoch RSI (14) | 54.23 | Neutral |
| CCI (20) | -60.77 | Neutral |
| Williams %R (14) | -73.61 | Info |
| MACD (12,26,9) | — | Neutral |
| ROC (12) | -3.32 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 26.39 | Neutral |
| TRIX (15) | — | Neutral |
| Awesome (5,34) | -2.20 | Sell |
| Ultimate (7,14,28) | 39.78 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 9.86 | Buy |
| ADX (14) | 10.49 | Neutral |
| ATR (14) | 0.78 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40.
SMA50 and SMA200 values are not provided, so those moving-average levels are not disclosed here. Support is at $9.49 and resistance is at $16.85, framing the near-term trading range.
The verified 30-day range spans from $6.18 to $16.98, reflecting potential movement within that window. The asset’s annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.49 | $10.20 | $14.23 | 0% | Neutral | |
| $6.19 | $9.47 | $15.68 | -7% | Neutral | |
| $4.77 | $8.09 | $14.58 | -21% | Bearish | |
| $4.39 | $8.17 | $15.68 | -20% | Bearish | |
| $3.96 | $8.04 | $16.27 | -21% | Bearish | |
| $4.13 | $9.12 | $19.29 | -11% | Neutral | |
| $5.15 | $11.43 | $25.14 | +12% | Neutral | |
| $5.37 | $11.94 | $27.18 | +17% | Neutral | |
| $5.41 | $12.02 | $27.66 | +18% | Neutral | |
| $4.62 | $10.26 | $23.60 | +1% | Neutral | |
| $7.51 | $16.69 | $38.39 | +64% | Bullish | |
| $8.99 | $19.99 | $45.97 | +96% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.49 | $10.20 | $12.93 | +0.00% |
| August 2026 | $8.04 | $10.01 | $13.13 | -1.87% |
| September 2026 | $8.02 | $10.21 | $13.80 | +1.99% |
| October 2026 | $8.31 | $10.77 | $14.93 | +5.54% |
| November 2026 | $7.98 | $10.51 | $14.87 | -2.40% |
| December 2026 | $7.38 | $9.88 | $14.23 | -6.04% |
Click any year to see its month-by-month CNXU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CNXU is projected to trade between $9.49 and $14.23, averaging $10.20 — a potential gain of 0% from today's $10.20. A consolidation phase looks the most probable path here.
Conexeu Sciences Inc.'s 2027 outlook centres on $9.47, within a $6.19 to $15.68 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. Price action looks broadly range-bound.
By 2028, CNXU could reach as high as $14.58, with a base case around $8.09 and support toward $4.77 — roughly -21% from $10.20. Expect choppier, lower action through this leg of the cycle.
Expect CNXU to range from $4.39 to $15.68 through 2029. The $8.17 average target implies a -20% move from current prices. That is up +1% on the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The CNXU price prediction for 2030 points to an average of $8.04 (low $3.96, high $16.27) — a potential decline of -21% on today's $10.20. Expect choppier, lower action through this leg of the cycle.
In 2031, CNXU is projected to trade between $4.13 and $19.29, averaging $9.12 — a potential decline of -11% from today's $10.20. That is up +13% on the projected 2030 average. Price action looks broadly range-bound.
Conexeu Sciences Inc.'s 2032 outlook centres on $11.43, within a $5.15 to $25.14 range. That is up +25% on the projected 2031 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, CNXU could reach as high as $27.18, with a base case around $11.94 and support toward $5.37 — roughly +17% from $10.20. Price action looks broadly range-bound.
Expect CNXU to range from $5.41 to $27.66 through 2034. The $12.02 average target implies a +18% move from current prices. That is up +1% on the projected 2033 average. A consolidation phase looks the most probable path here.
The CNXU price prediction for 2035 points to an average of $10.26 (low $4.62, high $23.60) — a potential gain of +1% on today's $10.20. Price action looks broadly range-bound.
In 2040, CNXU is projected to trade between $7.51 and $38.39, averaging $16.69 — a potential gain of +64% from today's $10.20. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Conexeu Sciences Inc.'s 2050 outlook centres on $19.99, within a $8.99 to $45.97 range. That is up +20% on the projected 2040 average. That marks a +96% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CNXU today (≈ 98.039216 CNXU) could be worth
$1,959.57
+$959.57 (+96%) by 2050 · US Dollar
Based on the average projected CNXU price of $19.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNXUwould be worth at today's price.
$1,000 invested in CNXU on May 21, 2026 (≈ 76.511096 CNXU) would be worth
$780.41
-$219.59 (-22.0%) today · 0.78× · US Dollar
Based on a CNXU entry price of $13.07 vs. today's $10.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.86 | $939.23 | -6.1% |
| 1 month ago | $13.02 | $783.41 | -21.7% |
| All time ago | $13.07 | $780.41 | -22.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNXU forecast.
$20.00 is within our bullish range by 2032, but above the base case.
Implied market cap at $20.00: $535.17M
Looking at the multi-year forecast, the 2030 outlook shows an average price of $8.13 with a -20.6% ROI and BEARISH sentiment, highlighting a mid-term weakness relative to today.
By 2040 the forecast turns bullish, with an average price of $16.70 and a 63% ROI, accompanied by a BULLISH sentiment signal.
In 2050 the average price is projected at $20.04 with a 95.7% ROI, again with a BULLISH sentiment. These later-year gains contrast with the earlier bearish stretch and illustrate a potential long-run uplift from the mid-2020s through 2050.
Between 2026 and 2029 the model shows near-term volatility and negative returns: 2026 avg $10.24 (ROI 0), 2027 avg $9.55 (ROI -6.7), 2028 avg $8.08 (ROI -21.1), and 2029 avg $8.20 (ROI -19.9). The 2031 to 2035 period is mixed-to-neutral, with 2031 avg $9.09 (ROI -11.2) and 2032–2035 showing neutral signals with progressively higher upside potential in some years (2032 avg $11.52, 2033 avg $12.07, 2034 avg $11.97, 2035 avg $10.30).
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $8.13 with a -20.6% ROI and BEARISH sentiment. The range for 2030 is min $4.00 and max $16.45.
The forecast presents a mixed outlook. Near term (2026) shows an avg of $10.24 with 0% ROI and NEUTRAL sentiment, followed by declines into 2029 (e.g., 2027 avg $9.55; 2028 avg $8.08; 2029 avg $8.20). Longer term, 2040 shows a bullish 63% ROI and 2050 shows 95.7% ROI, with BEARISH sentiment easing into NEUTRAL and then BULLISH.
Yes—the forecast for 2050 lists an avg price of $20.04 with a 95.7% ROI and a BULLISH sentiment, and the max for that year is $46.10.
RSI14 is 40 and sentiment is NEUTRAL. The 30-day range spans from $6.18 to $16.98, with a near-term support at $9.49 and resistance at $16.85. Annualized volatility is 100%.
The 2026 forecast shows min $9.49, avg $10.24, max $14.27 with ROI 0% and sentiment NEUTRAL.
Conexeu Sciences Inc. Community Discussion
0Share your Conexeu Sciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.